Vanda Pharmaceuticals Inc. Cash Flow Statement
VNDA|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Vanda Pharmaceuticals Inc. generated $13M in operating cash flow and $12M in free cash flow in FY2025. Free cash flow margin was 6.4% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $2.5M | $6.3M | $33.2M | $23.3M | $115.6M | $25.2M | -$15.6M | -$18.0M | -$39.9M | $20.2M | -$21.1M | -$28.6M | -$9.8M | $7.2M | -$35.9M |
| Depreciation & Amortization | $920.0K | $1.2M | $1.4M | $1.4M | $1.4M | $1.4M | $1.2M | $935.0K | $582.0K | $530.0K | $432.0K | $633.0K | $469.0K | $336.0K | $442.0K |
| Operating Cash Flow | $12.8M | $32.0M | $64.2M | $51.8M | $45.9M | $30.0M | -$2.0M | -$8.1M | $12.4M | -$81.6M | -$39.6M | -$44.9M | -$28.4M | -$10.9M | $169.3M |
| Capital Expenditures | $383.0K | $679.0K | $552.0K | $1.8M | $1.0M | $368.0K | $1.7M | $1.4M | $2.5M | $769.0K | $176.0K | $2.0M | $275.0K | $275.0K | $275.0K |
| Free Cash Flow | $12.4M | $31.3M | $63.7M | $50.0M | $44.9M | $29.6M | -$3.6M | -$9.5M | $9.9M | -$82.3M | -$39.8M | -$46.9M | -$28.7M | -$11.2M | $169.1M |
| FCF Margin | 6.5% | 12.3% | 23.7% | 20.1% | 19.8% | 15.3% | -2.2% | -6.5% | 9.0% | -164.1% | -117.4% | -143.4% | -91.7% | -31.3% | 3717.3% |